Jeff Aronin

1 item

April 29, 2026

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy
Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first‑in‑class selective dopamine D1 receptor [...]

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy